Genoray Co Ltd
Genoray Co Ltd is a South Korean company specializing in the development, production, and sale of medical equipment and related technologies, primarily focused on diagnostic imaging and radiation therapy solutions.
Business. Genoray Co Ltd (122310.KQ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. It is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Genoray Co Ltd (122310.KQ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. It is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Genoray maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.21, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.59, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential near-term liquidity constraints.
Profitability metrics show a return on equity (ROE) of 2.27% and a return on assets (ROA) of 1.67%, both below the typical thresholds for high-performing firms in the Advanced Medical Equipment & Technology industry. These figures suggest that Genoray is generating modest returns relative to its equity and asset base.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in South Korea, where the company is headquartered.
Looking ahead, Genoray's growth trajectory appears modest. The company's capital expenditures are negative, indicating a reduction in investment in long-term assets, which may signal a strategic shift or financial constraints. While the company's operating cash flow is positive at 4.63 billion KRW, the free cash flow is significantly lower at 1.8 billion KRW, reflecting the impact of capital expenditures.
Risk factors include the company's negative net cash position and the potential for liquidity constraints. The dilution risk is currently assessed as low, with no significant dilution sources identified in the latest filings. However, the company's reliance on a single business segment and geographic market increases its vulnerability to sector-specific downturns.
Recent events include the company's continued focus on its core medical equipment business, with no major acquisitions or divestitures reported in the latest financial statements. The company's recent financial filings do not indicate any material changes in its business strategy or operations.
- Genoray maintains a conservative capital structure with a low debt-to-equity ratio of 0.21.
- The company's ROE and ROA are below industry benchmarks, indicating modest profitability.
- Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
- Free cash flow is significantly lower than operating cash flow, suggesting capital expenditure constraints.
- The company's liquidity position is medium, with a current ratio of 2.59 and a negative net cash position after debt.
Bull / Bear case
Generated · model-assistedThe company's cash conversion ratio of 2.13 is the best in its peer group of 205 firms.
Free cash flow surged 245.6% year-over-year to 5.5 billion KRW in the latest period.
Revenue grew at a 9.8% compound annual rate over the last four fiscal years.
Genoray faces high credit risk according to the provided risk flag assessment for the issuer.
Long-term debt increased to 34.0 billion KRW in the latest period, up from 12.9 billion in 2022.
The debt-to-equity ratio of 0.21 is below the cohort median, indicating higher leverage relative to peers.
Return on equity of 2.3% remains low despite being above the negative cohort median.
In focus — financials by report
Revenue KRW 82.60B, +11,2% YoY; Operating income −0,3% YoY.
- ▍Revenue KRW 82.60B, +11,2% YoY
- ▍Operating income −0,3% YoY
- ▍Net income −3,0% YoY
- ▍Free cash flow −81,7% YoY
- ▍Net margin 16.8%
Revenue KRW 74.29B; Operating income KRW 14.97B.
- ▍Revenue KRW 74.29B
- ▍Operating income KRW 14.97B
- ▍Net margin 19.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Genoray Co Ltd Market data — financials · 2026-05-26